Valuation: Galapagos NV

Market Cap 1.71B 1.95B 1.61B 1.47B 2.75B 187B 2.77B 19.34B 7.5B 95.31B 7.33B 7.17B 309B P/E 2026 *
-13.9x
P/E 2027 * -5.66x
Enterprise Value -718M -818M -675M -617M -1.15B -78.31B -1.16B -8.1B -3.14B -39.93B -3.07B -3B -129B EV / Sales 2026 *
-6.12x
EV / Sales 2027 * 2.37x
Free-Float
74.64%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 53 12/05/2025
Director of Finance/CFO 41 07/07/2025
Chief Operating Officer - 01/06/2026
Director TitleAgeSince
Director/Board Member 63 22/10/2019
Director/Board Member 49 07/10/2024
Director/Board Member 53 12/05/2025
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00% - - 1.96B
-0.18%+4.35%+4.23%+30.02% 47.86B
-0.92%-0.00%+44.18%+32.82% 44.46B
-1.54%+4.26%+10.29%+90.63% 41.85B
-1.84%-3.16%+329.18%+543.12% 41.34B
-0.62%-0.06%+10.15%+46.02% 30.04B
-1.73%-0.05%+24.19%+151.80% 17.59B
-5.47%-9.14% - - 15.6B
-3.55%+1.95%+21.97%+39.13% 15.69B
-0.96%+9.49%-8.94% - 13.93B
Average -1.68%+2.66%+54.41%+133.36% 29.82B
Weighted average by Cap. -1.46%+1.88%+67.87%+141.55%

Financials

2026 *2027 *
Net sales 117M 134M 110M 101M 188M 12.79B 190M 1.32B 513M 6.52B 502M 491M 21.15B 84.62M 96.41M 79.54M 72.72M 136M 9.24B 137M 955M 370M 4.71B 362M 354M 15.27B
Net income -40.7M -46.37M -38.25M -34.97M -65.36M -4.44B -65.84M -459M -178M -2.26B -174M -170M -7.34B -213M -242M -200M -183M -342M -23.21B -344M -2.4B -931M -11.83B -910M -890M -38.37B
Net Debt -2.43B -2.77B -2.28B -2.09B -3.9B -265B -3.93B -27.44B -10.64B -135B -10.4B -10.17B -438B -1.51B -1.72B -1.42B -1.3B -2.43B -165B -2.45B -17.07B -6.62B -84.15B -6.47B -6.33B -273B
Logo Galapagos NV
Lakefront Biotherapeutics NV (formerly Galapagos NV) is a biotechnology company built to bring meaningful medicines to patients with serious diseases in therapeutic areas of unmet need. The Company combines world-class deal making expertise with capital to identify, acquire, and advance promising opportunities that have the potential to drive value for patients and shareholders. Applying a modality-agnostic asset selection approach and operational flexibility, Lakefront Biotherapeutics NV prioritizes oncology and immunology & inflammation programs with clear clinical proof-of-concept in emerging areas.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B